全文获取类型
收费全文 | 3479篇 |
免费 | 299篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 80篇 |
妇产科学 | 68篇 |
基础医学 | 495篇 |
口腔科学 | 23篇 |
临床医学 | 273篇 |
内科学 | 837篇 |
皮肤病学 | 40篇 |
神经病学 | 286篇 |
特种医学 | 144篇 |
外国民族医学 | 2篇 |
外科学 | 458篇 |
综合类 | 31篇 |
一般理论 | 1篇 |
预防医学 | 351篇 |
眼科学 | 47篇 |
药学 | 211篇 |
肿瘤学 | 423篇 |
出版年
2023年 | 14篇 |
2022年 | 38篇 |
2021年 | 56篇 |
2020年 | 33篇 |
2019年 | 60篇 |
2018年 | 97篇 |
2017年 | 83篇 |
2016年 | 69篇 |
2015年 | 68篇 |
2014年 | 111篇 |
2013年 | 156篇 |
2012年 | 283篇 |
2011年 | 275篇 |
2010年 | 149篇 |
2009年 | 125篇 |
2008年 | 221篇 |
2007年 | 243篇 |
2006年 | 238篇 |
2005年 | 230篇 |
2004年 | 195篇 |
2003年 | 151篇 |
2002年 | 107篇 |
2001年 | 91篇 |
2000年 | 78篇 |
1999年 | 64篇 |
1998年 | 41篇 |
1997年 | 24篇 |
1996年 | 25篇 |
1995年 | 33篇 |
1994年 | 21篇 |
1993年 | 22篇 |
1992年 | 48篇 |
1991年 | 34篇 |
1990年 | 39篇 |
1989年 | 35篇 |
1988年 | 38篇 |
1987年 | 22篇 |
1986年 | 18篇 |
1985年 | 19篇 |
1984年 | 24篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1979年 | 14篇 |
1977年 | 10篇 |
1976年 | 10篇 |
1975年 | 9篇 |
1974年 | 8篇 |
1973年 | 8篇 |
1972年 | 6篇 |
1970年 | 6篇 |
排序方式: 共有3792条查询结果,搜索用时 15 毫秒
81.
Meschi Nastaran Vanhoenacker Anke Strijbos Olaf Camargo dos Santos Bernardo Rubbers Eléonore Peeters Valerie Curvers Frederik Van Mierlo Maarten Geukens Arne Fieuws Steffen Verbeken Eric Lambrechts Paul 《Clinical oral investigations》2020,24(12):4439-4453
Clinical Oral Investigations - The aim of this study was to assess in a multi-modular manner the bone healing 1 year post root-end surgery (RES) with leukocyte- and platelet-rich fibrin... 相似文献
82.
83.
84.
Arjan PM de Brouwer Sander B Nabuurs Ingrid EC Verhaart Astrid R Oudakker Roel Hordijk Helger G Yntema Jannet M Hordijk-Hos Krysta Voesenek Bert BA de Vries Ton van Essen Wei Chen Hao Hu Jamel Chelly Johan T den Dunnen Vera M Kalscheuer Annemieke M Aartsma-Rus Ben CJ Hamel Hans van Bokhoven Tjitske Kleefstra 《European journal of human genetics : EJHG》2014,22(4):480-485
We have identified a deletion of 3 base pairs in the dystrophin gene (DMD), c.9711_9713del, in a family with nonspecific X-linked intellectual disability (ID) by sequencing of the exons of 86 known X-linked ID genes. This in-frame deletion results in the deletion of a single-amino-acid residue, Leu3238, in the brain-specific isoform Dp71 of dystrophin. Linkage analysis supported causality as the mutation was present in the 7.6 cM linkage interval on Xp22.11–Xp21.1 with a maximum positive LOD score of 2.41 (MRX85 locus). Molecular modeling predicts that the p.(Leu3238del) deletion results in the destabilization of the C-terminal domain of dystrophin and hence reduces the ability to interact with β-dystroglycan. Correspondingly, Dp71 protein levels in lymphoblastoid cells from the index patient are 6.7-fold lower than those in control cell lines (P=0.08). Subsequent determination of the creatine kinase levels in blood of the index patient showed a mild but significant elevation in serum creatine kinase, which is in line with impaired dystrophin function. In conclusion, we have identified the first DMD mutation in Dp71 that results in ID without muscular dystrophy. 相似文献
85.
86.
Stefan Zeuzem Thomas Berg Edward Gane Peter Ferenci Graham R. Foster Michael W. Fried Christophe Hezode Gideon M. Hirschfield Ira Jacobson Igor Nikitin Paul J. Pockros Fred Poordad Jane Scott Oliver Lenz Monika Peeters Vanitha Sekar Goedele De Smedt Rekha Sinha Maria Beumont-Mauviel 《Gastroenterology》2014
87.
Lize Bollen Marijke Peetermans Miet Peeters Kristel Van Steen Marc F. Hoylaerts Paul J. Declerck Peter Verhamme Ann Gils 《Thrombosis research》2014
Background
Both activated Thrombin Activatable Fibrinolysis Inhibitor (TAFI) and active Plasminogen Activator Inhibitor-1 (PAI-1) attenuate fibrinolysis and may therefore contribute to the pathophysiology of Venous ThromboEmbolism (VTE). Whether increased TAFI and/or PAI-1 concentrations are associated with VTE is unclear.Objective
To study an association of impaired fibrinolysis and VTE using a comprehensive panel of in-house developed assays measuring intact TAFI, activation peptide of TAFI (AP-TAFI), PAI-1 antigen, endogenous PAI-1:t-PA complex (PAI-1:t-PA) and active PAI-1 levels in 102 VTE patients and in 113 healthy controls (HC).Results
Active PAI-1 was significantly higher in VTE patients compared to HC (20.9 [9.6-37.8] ng/ml vs. 6.2 [3.5-9.7] ng/ml, respectively). Active PAI-1 was the best discriminator with an area under the ROC curve and 95% confidence interval (AUROC [95%CI]) of 0.84 [0.79-0.90] compared to 0.75 [0.68-0.72] for PAI-1:t-PA, 0.65 [0.58-0.73] for PAI-1 antigen, 0.62 [0.54-0.69] for AP-TAFI and 0.51 [0.44-0.59] for intact TAFI. Using ROC analysis, we defined an optimal cut-off of 12.8 ng/ml for active PAI-1, with corresponding sensitivity of 71 [61–79] % and specificity of 89 [82–94] %. A lack of association with the time between VTE event and sample collection or with the intake of anticoagulant treatment suggests that active PAI-1 levels are sustainable high in VTE patients.Conclusions
This case–control study emphasizes the clinical importance of measuring active PAI-1 instead of PAI-1 antigen and identifies active PAI-1 as a potential marker of VTE. Prognostic studies will need to address the clinical significance of active PAI-1 as biomarker. 相似文献88.
89.